Dynamic Advisor Solutions LLC Buys 299 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Dynamic Advisor Solutions LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 20.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,770 shares of the medical research company’s stock after buying an additional 299 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in IQVIA were worth $312,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of IQV. American National Bank & Trust bought a new stake in IQVIA in the first quarter worth $26,000. ST Germain D J Co. Inc. lifted its position in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in IQVIA in the fourth quarter worth $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA in the fourth quarter worth $44,000. Finally, Zions Bancorporation N.A. increased its stake in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Mizuho reduced their target price on IQVIA from $210.00 to $190.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. Truist Financial reduced their target price on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research note on Thursday, April 10th. HSBC lowered IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. UBS Group reduced their target price on IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. reduced their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a research note on Monday, May 19th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $226.32.

IQVIA Stock Up 0.3%

Shares of IQVIA stock opened at $154.63 on Friday. The firm’s 50 day moving average price is $148.02 and its 200-day moving average price is $176.42. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The company has a market cap of $26.75 billion, a P/E ratio of 21.07, a PEG ratio of 1.69 and a beta of 1.28.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the firm earned $2.54 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.